NASDAQ:ATRS - Antares Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.53 +0.01 (+0.40 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$2.53
Today's Range$2.50 - $2.5750
52-Week Range$1.58 - $4.09
Volume549,811 shs
Average Volume1.17 million shs
Market Capitalization$395.20 million
P/E Ratio-23.00
Dividend YieldN/A
Beta0.19

About Antares Pharma (NASDAQ:ATRS)

Antares Pharma logoAntares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Debt-to-Equity Ratio0.88
Current Ratio2.94
Quick Ratio2.39

Price-To-Earnings

Trailing P/E Ratio-23.00
Forward P/E Ratio-31.63
P/E GrowthN/A

Sales & Book Value

Annual Sales$54.51 million
Price / Sales7.28
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book12.05

Profitability

EPS (Most Recent Fiscal Year)($0.11)
Net Income$-16,740,000.00
Net Margins-32.96%
Return on Equity-52.74%
Return on Assets-23.67%

Miscellaneous

Employees111
Outstanding Shares156,830,000

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) released its quarterly earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The specialty pharmaceutical company had revenue of $12.70 million for the quarter, compared to the consensus estimate of $12.85 million. Antares Pharma had a negative net margin of 32.96% and a negative return on equity of 52.74%. View Antares Pharma's Earnings History.

What price target have analysts set for ATRS?

3 brokerages have issued 12-month price targets for Antares Pharma's shares. Their forecasts range from $3.00 to $5.00. On average, they anticipate Antares Pharma's share price to reach $4.00 in the next year. View Analyst Ratings for Antares Pharma.

Who are some of Antares Pharma's key competitors?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:
  • Mr. Robert F. Apple, Chief Exec. Officer, Pres and Director (Age 52)
  • Mr. Fred M. Powell CPA, Exec. VP & CFO (Age 57)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. and Corp. Controller (Age 55)
  • Mr. Peter J. Graham Esq., Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51)
  • Edward Kessig, VP of Sales

Has Antares Pharma been receiving favorable news coverage?

News stories about ATRS stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Antares Pharma earned a media sentiment score of 0.08 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 46.23 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.83%), Wells Fargo & Company MN (1.23%), JW Asset Management LLC (1.13%), Russell Investments Group Ltd. (0.57%), Schwab Charles Investment Management Inc. (0.45%) and Guggenheim Capital LLC (0.34%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Which major investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., JW Asset Management LLC, Guggenheim Capital LLC and A.R.T. Advisors LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella, Leonard S Jacob and Thomas J Garrity. View Insider Buying and Selling for Antares Pharma.

Which major investors are buying Antares Pharma stock?

ATRS stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., JPMorgan Chase & Co., Wells Fargo & Company MN, Schwab Charles Investment Management Inc. and MetLife Investment Advisors LLC. View Insider Buying and Selling for Antares Pharma.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $2.53.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $395.20 million and generates $54.51 million in revenue each year. The specialty pharmaceutical company earns $-16,740,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 111 workers across the globe.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]


MarketBeat Community Rating for Antares Pharma (ATRS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  212 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  350
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Antares Pharma (NASDAQ:ATRS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Antares Pharma in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 58.10%. The high price target for ATRS is $5.00 and the low price target for ATRS is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.253.25
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.0750$3.95
Price Target Upside: 58.10% upside81.82% upside105.81% upside138.67% upside

Antares Pharma (NASDAQ:ATRS) Consensus Price Target History

Price Target History for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ:ATRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/8/2018HC WainwrightSet Price TargetBuy$4.00LowView Rating Details
10/23/2017Piper Jaffray CompaniesSet Price TargetBuy$3.00N/AView Rating Details
6/23/2017Chardan CapitalInitiated CoverageBuy$5.00HighView Rating Details
4/20/2017Raymond JamesInitiated CoverageStrong-Buy$4.30LowView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Antares Pharma (NASDAQ:ATRS) Earnings History and Estimates Chart

Earnings by Quarter for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ:ATRS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.04)
2019 EPS Consensus Estimate: $0.08
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.02)($0.02)($0.02)
Q2 20182($0.03)($0.01)($0.02)
Q3 20183($0.02)$0.01$0.00
Q4 20183($0.02)$0.04$0.01
Q1 20191$0.00$0.00$0.00
Q2 20191$0.02$0.02$0.02
Q3 20191$0.03$0.03$0.03
Q4 20191$0.03$0.03$0.03

Antares Pharma (NASDAQ ATRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.0280)($0.04)$12.85 million$12.70 millionViewN/AView Earnings Details
3/13/2018Q4 2017($0.03)($0.02)$15.44 million$14.00 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.03)($0.03)$14.01 million$15.10 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.03)($0.02)$12.99 million$13.42 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.04)($0.03)$12.10 million$12.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.04)($0.03)$12.77 million$14.20 millionViewN/AView Earnings Details
11/9/2016Q316($0.03)($0.04)$11.15 million$13.50 millionViewListenView Earnings Details
8/9/2016Q216($0.04)($0.04)$11.00 million$12.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details
11/5/2015Q3 15($0.03)($0.04)$10.14 million$11.09 millionViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.07)($0.05)$6.92 million$6.57 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details
5/9/2014Q114($0.04)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.01)($0.01)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.01)($0.02)ViewN/AView Earnings Details
5/9/2011Q1 2011($0.02)($0.02)ViewN/AView Earnings Details
3/14/2011Q4 2010($0.02)($0.02)ViewN/AView Earnings Details
11/10/2010Q3 2010($0.02)($0.02)ViewN/AView Earnings Details
8/12/2010Q2 2010($0.02)($0.02)ViewN/AView Earnings Details
5/13/2010Q1 2010($0.04)($0.02)ViewN/AView Earnings Details
3/23/2010Q4 2009($0.03)($0.03)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.03)($0.04)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.06)($0.03)ViewN/AView Earnings Details
5/13/2009Q1 2009($0.06)($0.04)ViewN/AView Earnings Details
3/25/2009Q4 2008($0.05)($0.04)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.06)($0.05)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.05)($0.05)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.04)($0.05)ViewN/AView Earnings Details
3/26/2008Q4 2007($0.03)($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Antares Pharma (NASDAQ:ATRS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Antares Pharma (NASDAQ ATRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 37.06%
Insider Trading History for Antares Pharma (NASDAQ:ATRS)
Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ ATRS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2018Jacques GonellaDirectorSell200,000$2.54$508,000.0011,286,413View SEC Filing  
5/15/2018Jacques GonellaDirectorSell200,000$2.50$500,000.0011,486,413View SEC Filing  
5/11/2018Jacques GonellaDirectorSell200,000$2.42$484,000.0011,686,413View SEC Filing  
5/9/2018Jacques GonellaDirectorSell300,000$2.47$741,000.0011,936,413View SEC Filing  
10/9/2017Leonard S JacobDirectorSell230,000$4.05$931,500.00View SEC Filing  
10/3/2017Thomas J GarrityDirectorSell30,000$3.50$105,000.00View SEC Filing  
6/9/2017Fred M PowellInsiderBuy130,000$2.79$362,700.00331,434View SEC Filing  
4/5/2017Robert F AppleCEOSell40,000$3.00$120,000.00927,002View SEC Filing  
4/4/2017Leonard S JacobDirectorSell41,762$2.89$120,692.18238,885View SEC Filing  
4/4/2017Robert F AppleCEOSell37,000$3.00$111,000.00927,002View SEC Filing  
4/3/2017Leonard S JacobDirectorSell20,000$2.88$57,600.00238,885View SEC Filing  
3/31/2017Thomas J GarrityDirectorSell30,000$2.91$87,300.00190,213View SEC Filing  
12/9/2016Fred M PowellInsiderBuy100,000$2.03$203,000.00100,000View SEC Filing  
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.0020,000View SEC Filing  
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00270,216View SEC Filing  
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00218,885View SEC Filing  
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00517,164View SEC Filing  
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.0038,172View SEC Filing  
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00708,734View SEC Filing  
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00368,918View SEC Filing  
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00245,976View SEC Filing  
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00708,734View SEC Filing  
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Antares Pharma (NASDAQ ATRS) News Headlines

Source:
DateHeadline
Antares Pharma, Inc. (ATRS) Expected to Post Quarterly Sales of $14.44 MillionAntares Pharma, Inc. (ATRS) Expected to Post Quarterly Sales of $14.44 Million
www.americanbankingnews.com - May 19 at 1:55 AM
Jacques Gonella Sells 200,000 Shares of Antares Pharma, Inc. (ATRS) StockJacques Gonella Sells 200,000 Shares of Antares Pharma, Inc. (ATRS) Stock
www.americanbankingnews.com - May 18 at 7:39 PM
 Analysts Anticipate Antares Pharma, Inc. (ATRS) Will Announce Earnings of -$0.02 Per Share Analysts Anticipate Antares Pharma, Inc. (ATRS) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - May 17 at 11:15 PM
Antares Pharma, Inc. (ATRS) Given Average Recommendation of "Buy" by BrokeragesAntares Pharma, Inc. (ATRS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 17 at 1:39 AM
Antares Pharma, Inc. (ATRS) Director Sells $500,000.00 in StockAntares Pharma, Inc. (ATRS) Director Sells $500,000.00 in Stock
www.americanbankingnews.com - May 16 at 7:52 PM
Form 4 ANTARES PHARMA, INC. For: May 10 Filed by: GONELLA JACQUESForm 4 ANTARES PHARMA, INC. For: May 10 Filed by: GONELLA JACQUES
www.streetinsider.com - May 15 at 8:19 AM
Antares Pharma, Inc. (ATRS) Director Sells $484,000.00 in StockAntares Pharma, Inc. (ATRS) Director Sells $484,000.00 in Stock
www.americanbankingnews.com - May 14 at 7:40 PM
ATRS: Makena Maturing Quickly, Providing 1Q:18 BoostATRS: Makena Maturing Quickly, Providing 1Q:18 Boost
finance.yahoo.com - May 14 at 5:25 PM
Antares Pharma, Inc. (ATRS) to Post FY2018 Earnings of ($0.09) Per Share, Zacks Investment Research ForecastsAntares Pharma, Inc. (ATRS) to Post FY2018 Earnings of ($0.09) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - May 14 at 3:49 AM
Form 4 ANTARES PHARMA, INC. For: May 09 Filed by: GONELLA JACQUESForm 4 ANTARES PHARMA, INC. For: May 09 Filed by: GONELLA JACQUES
www.streetinsider.com - May 12 at 6:03 PM
Antares Pharma, Inc. (ATRS) Director Jacques Gonella Sells 300,000 SharesAntares Pharma, Inc. (ATRS) Director Jacques Gonella Sells 300,000 Shares
www.americanbankingnews.com - May 11 at 7:41 PM
Antares Pharma, Inc. (ATRS) Expected to Post FY2018 Earnings of ($0.05) Per ShareAntares Pharma, Inc. (ATRS) Expected to Post FY2018 Earnings of ($0.05) Per Share
www.americanbankingnews.com - May 11 at 11:04 AM
Brokers Issue Forecasts for Antares Pharma, Inc.s Q2 2018 Earnings (ATRS)Brokers Issue Forecasts for Antares Pharma, Inc.'s Q2 2018 Earnings (ATRS)
www.americanbankingnews.com - May 11 at 9:31 AM
Equities Analysts Set Expectations for Antares Pharma, Inc.s Q2 2018 Earnings (ATRS)Equities Analysts Set Expectations for Antares Pharma, Inc.'s Q2 2018 Earnings (ATRS)
www.americanbankingnews.com - May 11 at 9:31 AM
Antares Pharma (ATRS) Issues  Earnings Results, Misses Estimates By $0.01 EPSAntares Pharma (ATRS) Issues Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 10 at 5:30 PM
Edited Transcript of ATRS earnings conference call or presentation 8-May-18 12:30pm GMTEdited Transcript of ATRS earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 8:18 AM
Piper Jaffray Research Analysts Lower Earnings Estimates for Antares Pharma, Inc. (ATRS)Piper Jaffray Research Analysts Lower Earnings Estimates for Antares Pharma, Inc. (ATRS)
www.americanbankingnews.com - May 10 at 7:55 AM
Form 4 ANTARES PHARMA, INC. For: May 03 Filed by: GONELLA JACQUESForm 4 ANTARES PHARMA, INC. For: May 03 Filed by: GONELLA JACQUES
www.streetinsider.com - May 9 at 8:13 AM
BRIEF-Antares Pharma Reports Q1 Loss Per Share Of $0.04BRIEF-Antares Pharma Reports Q1 Loss Per Share Of $0.04
www.reuters.com - May 9 at 8:13 AM
Antares Pharmas (ATRS) CEO Robert Apple on Q1 2018 Results - Earnings Call TranscriptAntares Pharma's (ATRS) CEO Robert Apple on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:46 PM
Antares Pharma: 1Q Earnings SnapshotAntares Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 5:46 PM
Antares Pharma (ATRS) PT Set at $4.00 by HC WainwrightAntares Pharma (ATRS) PT Set at $4.00 by HC Wainwright
www.americanbankingnews.com - May 8 at 3:28 PM
Antares Pharma misses by $0.01, misses on revenueAntares Pharma misses by $0.01, misses on revenue
seekingalpha.com - May 8 at 8:10 AM
Antares Pharma Reports First Quarter 2018 Operating and Financial ResultsAntares Pharma Reports First Quarter 2018 Operating and Financial Results
finance.yahoo.com - May 8 at 8:10 AM
Jefferies Group Brokers Increase Earnings Estimates for Antares Pharma, Inc. (ATRS)Jefferies Group Brokers Increase Earnings Estimates for Antares Pharma, Inc. (ATRS)
www.americanbankingnews.com - May 4 at 5:49 AM
Antares Pharma (ATRS) Upgraded at ValuEngineAntares Pharma (ATRS) Upgraded at ValuEngine
www.americanbankingnews.com - May 4 at 12:20 AM
Analysts Issue Forecasts for Antares Pharma, Inc.s Q4 2018 Earnings (ATRS)Analysts Issue Forecasts for Antares Pharma, Inc.'s Q4 2018 Earnings (ATRS)
www.americanbankingnews.com - May 3 at 9:30 AM
Antares Pharma to Present at the Deutsche Bank Securities, Inc. 43rd Annual Health Care ConferenceAntares Pharma to Present at the Deutsche Bank Securities, Inc. 43rd Annual Health Care Conference
finance.yahoo.com - May 2 at 8:16 AM
$13.45 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter$13.45 Million in Sales Expected for Antares Pharma, Inc. (ATRS) This Quarter
www.americanbankingnews.com - May 2 at 3:54 AM
Antares Pharma (ATRS) Rating Increased to Strong-Buy at BidaskClubAntares Pharma (ATRS) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 1 at 9:12 AM
Antares Pharma to Report First Quarter 2018 Financial and Operating ResultsAntares Pharma to Report First Quarter 2018 Financial and Operating Results
finance.yahoo.com - May 1 at 8:16 AM
-$0.03 Earnings Per Share Expected for Antares Pharma, Inc. (ATRS) This Quarter-$0.03 Earnings Per Share Expected for Antares Pharma, Inc. (ATRS) This Quarter
www.americanbankingnews.com - April 30 at 11:20 AM
Antares Pharma Inc (ATRS) Given Average Recommendation of "Buy" by AnalystsAntares Pharma Inc (ATRS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 22 at 1:36 AM
Reviewing Antares Pharma (ATRS) and Interpace Diagnostics Gr (IDXG)Reviewing Antares Pharma (ATRS) and Interpace Diagnostics Gr (IDXG)
www.americanbankingnews.com - April 18 at 11:14 AM
Antares Pharma (ATRS) Raised to "Buy" at VetrAntares Pharma (ATRS) Raised to "Buy" at Vetr
www.americanbankingnews.com - April 17 at 4:47 PM
Antares Pharma (ATRS) Stock Rating Upgraded by VetrAntares Pharma (ATRS) Stock Rating Upgraded by Vetr
www.americanbankingnews.com - April 16 at 11:29 PM
Piper Jaffray Analysts Give Antares Pharma (ATRS) a $4.00 Price TargetPiper Jaffray Analysts Give Antares Pharma (ATRS) a $4.00 Price Target
www.americanbankingnews.com - April 15 at 11:43 PM
 Brokerages Anticipate Antares Pharma Inc (ATRS) Will Announce Quarterly Sales of $13.45 Million Brokerages Anticipate Antares Pharma Inc (ATRS) Will Announce Quarterly Sales of $13.45 Million
www.americanbankingnews.com - April 15 at 4:05 AM
Zacks: Brokerages Expect Antares Pharma Inc (ATRS) Will Announce Earnings of -$0.03 Per ShareZacks: Brokerages Expect Antares Pharma Inc (ATRS) Will Announce Earnings of -$0.03 Per Share
www.americanbankingnews.com - April 13 at 11:34 AM
Antares Pharma (ATRS) Raised to "Buy" at BidaskClubAntares Pharma (ATRS) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 13 at 10:01 AM
Antares Pharma (ATRS) Given a $5.00 Price Target at HC WainwrightAntares Pharma (ATRS) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 11 at 11:52 PM
3 Things In Biotech, April 7: Lillys Surprising Liver Data, Antaress Retry Is Go, EyeGate Looks Toward The Future3 Things In Biotech, April 7: Lilly's Surprising Liver Data, Antares's Retry Is Go, EyeGate Looks Toward The Future
seekingalpha.com - April 8 at 9:25 AM
Antares Pharma (ATRS) Downgraded by BidaskClubAntares Pharma (ATRS) Downgraded by BidaskClub
www.americanbankingnews.com - April 5 at 10:26 AM
FDA accepts Antares Pharmas resubmitted Xyosted marketing application, action date September 29; shares up 10% premarketFDA accepts Antares Pharma's resubmitted Xyosted marketing application, action date September 29; shares up 10% premarket
seekingalpha.com - April 5 at 10:02 AM
Antares Pharma (ATRS) Says Complete Response Resubmission Accepted by FDA; PDUFA Date Set for September 29Antares Pharma (ATRS) Says Complete Response Resubmission Accepted by FDA; PDUFA Date Set for September 29
www.streetinsider.com - April 5 at 10:02 AM
BRIEF-Antares Pharma Provides Xyosted™ Regulatory UpdateBRIEF-Antares Pharma Provides Xyosted™ Regulatory Update
www.reuters.com - March 29 at 8:19 AM
Antares Pharma (ATRS) Receves Minutes from Type A Meeting with FDA in Connection with XYOSTED NDAAntares Pharma (ATRS) Receves Minutes from Type A Meeting with FDA in Connection with XYOSTED NDA
www.streetinsider.com - March 29 at 8:19 AM
$13.45 Million in Sales Expected for Antares Pharma Inc (ATRS) This Quarter$13.45 Million in Sales Expected for Antares Pharma Inc (ATRS) This Quarter
www.americanbankingnews.com - March 29 at 5:52 AM
Antares Pharma Inc (ATRS) Receives Consensus Rating of "Buy" from BrokeragesAntares Pharma Inc (ATRS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 28 at 1:38 AM
ATRS: Xyosted Regulatory UpdateATRS: Xyosted Regulatory Update
finance.yahoo.com - March 27 at 5:19 PM

SEC Filings

Antares Pharma (NASDAQ:ATRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Antares Pharma (NASDAQ:ATRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Antares Pharma (NASDAQ ATRS) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.